We studied the effects of alkaline phosphatase (AP) on the secretory processes of the rat intrahepatic biliary epithelium as well as the role of the intrahepatic biliary epithelium in the uptake and biliary secretion of exogenous AP. The effects of acute and chronic administration of AP on bile secretory parameters were investigated in vivo in normal and bile duct ligated (BDL) rats and in vitro in isolated rat bile duct units (IBDU). In vivo, acute AP administration decreased bile flow and biliary bicarbonate excretion and abolished secretin choleresis in BDL rats but not in normal rats. On the contrary, the AP inhibitor, levamisole, increased in BDL rat bile flow and biliary bicarbonate excretion. The intrahepatic biliary epithelium plays a key role in determining the final composition of bile reaching the duodenum through the secretion and/or reabsorption of bile constituents. 1,2 Bicarbonate secretion in bile, a major function of the biliary epithelium, is driven by the apically located Cl Ϫ /HCO 3 Ϫ exchanger, which is functionally coupled with the cystic fibrosis transmembrane regulator (CFTR). 1-5 Secretin induces ductal choleresis by activating, via the cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) pathway, the CFTR and subsequently stimulating the Cl Ϫ /HCO 3 Ϫ exchanger. [3] [4] [5] We have recently shown that protein kinase A (PKA) is essential in the mechanism of secretin choleresis by showing that Rp-cAMPs, a specific PKA inhibitor, blocks both secretin-induced bicarbonate-rich choleresis and stimulation of the Cl Ϫ /HCO 3 Ϫ exchanger. 5 Once secretin is removed, the run-down of secretory stimulus is driven by the protein phosphatases 1 and/or 2A, because their inhibitor, okadaic acid, induces persistence of secretion even after removal of the hormone. 5 These experiments indicate that the process of secretin choleresis is modulated by a balance between the activities of kinases and phosphatases, with the object of this balance being the reversible phosphorylation of CFTR. In other cell types expressing CFTR, the basal activity of protein phosphatases is important in maintaining CFTR in the quiescent status. 6-8 Indeed, when protein phosphatases are pharmacologically blocked, CFTR undergoes activation with opening of Cl Ϫ conductance. 6 The secretory processes of the intrahepatic biliary epithelium are also regulated by adenosine triphosphate (ATP), which modulates the activities of CFTR and other Cl Ϫ channels. 9, 10 Alkaline phosphatase (AP) is a nonspecific protein phosphatase whose function is scarcely known. AP is markedly expressed in the apical pole of hepatocytes and cholangiocytes and is secreted in bile in large amounts. 11-14 Hepatic AP displays the function of ATPase, 11 and a role in endotoxin detoxification has recently been shown. 15 Although AP could theoretically influence the secretory processes of the biliary epithelium by acting as ATPase or by nonspecific protein phosphatase, the role of this enzyme in the regulation of processes underlying bile formation has not yet been studied.
We studied the effects of alkaline phosphatase (AP) on the secretory processes of the rat intrahepatic biliary epithelium as well as the role of the intrahepatic biliary epithelium in the uptake and biliary secretion of exogenous AP. The effects of acute and chronic administration of AP on bile secretory parameters were investigated in vivo in normal and bile duct ligated (BDL) rats and in vitro in isolated rat bile duct units (IBDU). In vivo, acute AP administration decreased bile flow and biliary bicarbonate excretion and abolished secretin choleresis in BDL rats but not in normal rats. On the contrary, the AP inhibitor, levamisole, increased in BDL rat bile flow and biliary bicarbonate excretion. In vitro, basal and secretin-stimulated Cl ؊ /HCO 3 ؊ exchanger activity in IBDU was immediately inhibited by AP intraluminal microinjection (apical exposure) but only after a prolonged exposure to the basolateral pole. Levamisole increased the Cl ؊ /HCO 3 ؊ exchanger activity of IBDU. A significant basolateral uptake of AP occurs in IBDU with a progressive transport to the apical domain. AP chronic treatment increased AP and ␥-glutamyltranspeptidase (␥-GT) activities in the intrahepatic bile ducts and hepatocyte canalicular pole, promoted enlargement of bile canaliculi, and decreased bile flow and biliary bicarbonate excretion. In conclusion, the intrahepatic biliary epithelium plays a role in the uptake and biliary secretion of serum AP. AP inhibits the secretory processes of the intrahepatic biliary epithelium and induces features of intrahepatic cholestasis after chronic administration. These findings indicate that AP plays an active role in down-regulating the secretory activities of the intrahepatic biliary epithelium. (HEPATOLOGY 2000;32:174-184.)
The intrahepatic biliary epithelium plays a key role in determining the final composition of bile reaching the duodenum through the secretion and/or reabsorption of bile constituents. 1, 2 Bicarbonate secretion in bile, a major function of the biliary epithelium, is driven by the apically located Cl Ϫ /HCO 3 Ϫ exchanger, which is functionally coupled with the cystic fibrosis transmembrane regulator (CFTR). [1] [2] [3] [4] [5] Secretin induces ductal choleresis by activating, via the cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) pathway, the CFTR and subsequently stimulating the Cl Ϫ /HCO 3 Ϫ exchanger. [3] [4] [5] We have recently shown that protein kinase A (PKA) is essential in the mechanism of secretin choleresis by showing that Rp-cAMPs, a specific PKA inhibitor, blocks both secretin-induced bicarbonate-rich choleresis and stimulation of the Cl Ϫ /HCO 3 Ϫ exchanger. 5 Once secretin is removed, the run-down of secretory stimulus is driven by the protein phosphatases 1 and/or 2A, because their inhibitor, okadaic acid, induces persistence of secretion even after removal of the hormone. 5 These experiments indicate that the process of secretin choleresis is modulated by a balance between the activities of kinases and phosphatases, with the object of this balance being the reversible phosphorylation of CFTR. In other cell types expressing CFTR, the basal activity of protein phosphatases is important in maintaining CFTR in the quiescent status. [6] [7] [8] Indeed, when protein phosphatases are pharmacologically blocked, CFTR undergoes activation with opening of Cl Ϫ conductance. 6 The secretory processes of the intrahepatic biliary epithelium are also regulated by adenosine triphosphate (ATP), which modulates the activities of CFTR and other Cl Ϫ channels. 9, 10 Alkaline phosphatase (AP) is a nonspecific protein phosphatase whose function is scarcely known. AP is markedly expressed in the apical pole of hepatocytes and cholangiocytes and is secreted in bile in large amounts. [11] [12] [13] [14] Hepatic AP displays the function of ATPase, 11 and a role in endotoxin detoxification has recently been shown. 15 Although AP could theoretically influence the secretory processes of the biliary epithelium by acting as ATPase or by nonspecific protein phosphatase, the role of this enzyme in the regulation of processes underlying bile formation has not yet been studied.
We investigated the role of AP in the regulation of the secretory activities of the rat intrahepatic biliary epithelium and the effects of chronic AP administration on bile secretion and liver morphology.
MATERIALS AND METHODS
Male Fisher 344 rats (225-250 g) were purchased from Harlan Sprague Dawley, Inc. (Indianapolis, IN), maintained on Good Laboratory Practice diet in pellet, and given water ad libitum. Study protocols were performed according to the institutional guidelines. AP (type VII NLA) from bovine intestinal mucosa and all the reagents were purchased from Sigma Chemical Co. (St. Louis, MO) unless otherwise indicated. In selected experiments, AP from bovine liver (Sigma; type IX) was also used.
Normal rats, 2-week bile duct-ligated (BDL) rats, and rats chronically treated with AP were surgically prepared for bile collection as previously described. 16 Bile duct ligation was performed as described. 16 When a steady-state bile flow was achieved (60-70 minutes from the beginning of bile collection), we infused, via the jugular vein, AP (1,200 U for 60 minutes), secretin (40 L/min for 30-50 minutes of 50 nmol/L secretin dissolved in Krebs-Henseleit bicarbonate [KRH] buffer plus 0.2% bovine serum albumin), glucagon (40 L/min for 40 minutes of 200 nmol/L glucagon dissolved in KRH buffer plus 0.2% bovine serum albumin), and taurocholate (TCA; 0.5 mol/min for 20 minutes in saline [i.e., NaCl 0.9%] at a flow rate of 40 L/min), and the effect on bile flow, bile salt (BS), bicarbonate, and AP secretion in bile was evaluated. Administration of saline or KRH plus bovine serum albumin without hormones, TCA, or AP in control rats did not significantly change bile flow and biliary bicarbonate excretion. Bile was collected every 10 minutes, bile volume was determined by weight, assuming a density of 1.0 g/mL, and bile flow was expressed as L/min/kg body weight. Bicarbonate concentration (measured as total CO 2 ) in bile was determined by a Natelson microgasometer (Scientific Industries, Bohemia, NY). Total biliary BS was determined as described. 17 AP in bile was measured by the method of Ohkubo et al. 11 In control experiments (protein controls), AP was inactivated by warming at 98°C for 10 minutes, and then the effect on bile flow and biliary bicarbonate excretion was evaluated in BDL rats. No detectable enzymic activity was found 11 after heat treatment of the AP solution infused in BDL rats.
Isolated rat bile duct units (IBDU) were prepared as previously described 18 with a viability (trypan blue exclusion) always higher than 98% (by counting all cells of IBDU). To evaluate the effect of AP, secretin, or AP plus secretin on ductal fluid secretion, the area of IBDU luminal spaces was measured by the video imaging technique. 18 Findings were expressed as percent changes with respect to baseline values (i.e., the values measured before application of secretin or AP). The Cl Ϫ /HCO 3 Ϫ exchanger activity was evaluated in IBDU as previously described 3, 5, 18 by measuring changes in intracellular pH (pH i ) during the maneuver of acute Cl Ϫ removal/readmission. pH i was measured using a microfluorimetric single-cell method (SPEX-AR-CM-micro system, Spex Industries, Edison NJ) and 2,7,bis(carboxyethyl)-5(6)-carboxy-fluorescein-acetoxymethylester (Molecular Probes Inc., Eugene, OR) as a fluorescent pH i indicator. 3, 5, 18 To evaluate the effect of apical exposure of IBDU to AP on Cl Ϫ /HCO 3 Ϫ exchanger activity, AP (20 U/mL in saline [i.e., 0.9% NaCl]) or saline (controls) was microinjected into the IBDU luminal space by using linear glass micropipettes prepared with a computercontrolled micropipette puller (Campden Instruments Limited, Sileby, United Kingdom). The microinjection was stopped as soon as the luminal space started to blow up; then the needle was gently retired.
In control experiments (protein controls), heat-inactivated AP (see above) solution was also used for perfusion, preincubation, or microinjection of IBDU.
To evaluate for apical uptake of AP in the biliary epithelium, a retrograde perfusion of the enzyme was performed. For this purpose, after cannulation of the common bile duct with PE 10 tubing (Clay adams, Parsippany, NJ), the portal tissue residue was isolated from parenchymal tissue by shaking in cold L-15 medium added with collagenase and pronase as described for IBDU isolation. 18 The portal tissue was then incubated for 2 hours in ␣ minimum essential medium culture medium at 37°C in a 95% O 2 /5% CO 2 incubator to allow recovery from enzyme treatment. Thereafter, AP (intestinal isoform, 20 U/mL dissolved in KRH) was infused through a nonrecirculating system at a flow rate of 0.1 mL/min for 30 minutes. After stopping perfusion, the portal tissue was minced and then stained for AP as described above.
The genetic expression of AP messenger RNA (mRNA) was examined in pure preparations of cholangiocytes from normal 19 and BDL 20 rats by reverse transcriptase-polymerase chain reaction (RT-PCR) using poly (A) ϩ mRNA obtained by Micro-Fast Track kit (Invitrogen, San Diego, CA). Specific primers for AP (sense 5Ј-CAT-GCAGTATGAGTTGAATCGGAA-3Ј and antisense 5Ј-GCTTCTT-GTCCGTGTCGCTC-3Ј, expected fragment length 346 bp) were designed from the sequence encoding the hepatic AP mRNA. 21, 22 Total rat liver and yeast transfer RNA were used as positive and negative controls, respectively. The comparability of mRNA used was assessed by RT-PCR for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 23 (GAPDH). AP fragment was subcloned into pGEM-4Z and sequenced using a Sequenase Version 2.0 kit (United States Biochemical, Cleveland, OH).
Histochemistry for AP was performed in IBDU and isolated rat hepatocyte couplets (IRHC), prepared as described, 24 before and after incubation with 20 U/mL AP by using Sigma Fast 5-Bromo-4-Chloro-3-Indolyl Phosphate/Nitro Blue Tetrazolium Tablets (BCIP/ NBT Alkaline Phosphatase substrate). 25 Each tablet dissolved in 10 mL deionized water yields a ready-to-use buffered solution containing BCIP/NBT, pH 9.5. Morphometric studies were performed in at least 50 sections of IBDU and in at least 100 couplets at different time intervals (0-30 minutes) after incubation with AP. The specific histochemical staining was localized, scored, and analyzed by an Olympus Cue-3 VS Image Analyzer (Melville, NY). The intensity of the staining (intensity units) was electronically evaluated in the whole cytoplasm as well as in the basolateral and apical regions (electronically delimited) of both hepatocytes and cholangiocytes. The results were expressed as the percent of the intensity units detected in the basolateral or apical region with respect to the whole cytoplasm. The intensity of cholangiocyte staining after retrograde injection of AP (see above) has been evaluated and expressed as the ratio between values observed in treated and control bile ducts.
For chronic administration, AP (2,000 U) in saline (i.e., 0.9% NaCl) was loaded into osmotic micropumps (Alza Pharmaceutical, Palo Alto, CA) implanted subcutaneously in normal rats. These micropumps released AP for 2 weeks (AP release, 5.9 U/h). Controls were treated only with saline or, in selected experiments, with heatinactivated AP. Bile secretory parameters were evaluated as for the acute administration of AP. Liver samples were processed for histology and histochemistry for AP and ␥-glutamyltranspeptidase (␥-GT) as described. 26, 27 Serum total BS was measured by a radioimmunoassay kit (ICN Biomedicals, Milan, Italy). Serum AP was measured by routine method.
Data are presented as arithmetic mean Ϯ SEM unless otherwise indicated. Statistical analysis was conducted using the paired or unpaired Student's t test as appropriate or the analysis of the variance when multiple comparisons were done.
RESULTS

Effect of Acute Administration of AP on Secretory Parameters In
Vivo and in IBDU. Acute administration of AP showed no appreciable effect on basal bile flow in normal rats (Fig. 1) . Secretin (50 nmol/L) did not alter bile flow in normal rats, and this was not affected by AP (Fig. 1) . In addition, AP did not change the choleretic effect of TCA or glucagon. In fact, TCA (0.5 mol/min) induced a similar increase in bile flow (Fig. 1) either when administered alone (ϩ34%) or when administered with AP (ϩ36%) indicating that the transport and choleretic effect of TCA was unchanged by AP. Glucagon (200 nmol/L) induced a similar increase of bile flow in AP-infused rats (ϩ25%) and in paired controls (ϩ22%, Fig. 1 ).
In BDL rats (2-week BDL), acute administration of AP inhibited basal bile flow (from 99.0 Ϯ 7.0 to 79.0 Ϯ 6.0 L/ min/kg body weight, P Ͻ .05; Fig. 2 ) and basal bicarbonate biliary secretion (from 2.90 Ϯ 0.15 to 2.04 Ϯ 0.11 Eq/min/ kg, P Ͻ .02; Fig. 2 ). Both bile flow and bicarbonate biliary secretion during AP administration (Fig. 2 ) were significantly (P Ͻ .05) lower when compared with paired controls. In addition, AP completely abolished secretin-induced choleresis in BDL rats. In fact, when secretin was administered alone in BDL rats, we found a significant increase in bile flow (from 104 Ϯ 9 to 153 Ϯ 14 L/min/kg) and biliary bicarbonate excretion (from 2.99 Ϯ 0. 17 to 5.54 Ϯ 0.26 Eq/min/kg, P Ͻ .01; Fig. 2 ), but these effects were absent in secretin plus AP-administered BDL rats (Fig. 2) . BS biliary secretion was unchanged by AP (data not shown). In selected control experiments (n ϭ 3; protein controls) heat-inactivated AP showed no measurable effects on basal bile flow, basal biliary bicarbonate excretion, and secretin choleresis of BDL rats.
Biliary AP secretion in basal conditions as well as after intravenous AP administration is shown in Fig. 3 . Both basal biliary concentration and secretion of AP were higher (P Ͻ .01) in BDL rats (156 Ϯ 19.2 U/L; 20.3 Ϯ 3.1 mU/min/kg) than in normal rats (64.8 Ϯ 12.1 U/L; 4.8 Ϯ 1.0 mU/min/kg). When AP was administered, its biliary concentration and secretion increased more than 6-fold over basal values both in normal and BDL rats (Fig. 3) . The total amount of AP excreted in bile after intravenous administration was more than 10-fold higher in BDL rats than in normal rats (P Ͻ .01).
To directly evaluate the effect of AP on fluid secretion in cholangiocytes, we measured changes in the area of IBDU luminal spaces during perfusion with AP. AP induced (Fig. 4 ) a progressive decrease of IBDU luminal space, which became significant (Ϫ35.7 Ϯ 11.31%; P Ͻ .05) 20 minutes after the onset of AP administration when compared with paired controls. However, secretin (50 nmol/L, 30-minute perfusion) induced a similar increase in the luminal space area in IBDU exposed to AP (ϩ34.9 Ϯ 8% ϭ difference between AP plus secretin vs. AP alone) than in controls exposed to saline (ϩ35.1 Ϯ 5% ϭ difference between secretin vs. saline), indicating that the stimulatory effect of secretin on fluid secretion in IBDU is unaffected by basolateral application of AP (Fig. 4) . Heat-inactivated AP showed no significant effect on the area of IBDU luminal space after 30-minute perfusion (n ϭ 3). Under the same experimental conditions, basal and secretinstimulated Cl Ϫ /HCO 3 Ϫ exchanger activity was not affected by perfusion with AP. The net pH i increase and the maximal rate of alkalinization (first 30 seconds) after Cl Ϫ removal, as well as the maximal rate of pH i recovery (first 30 seconds) after Cl Ϫ readmission, were similar during perfusion of IBDU with or FIG. 3 . Biliary AP secretion in normal and BDL rats in basal conditions and after intravenous administration of AP, secretin, or AP plus secretin. AP in bile was measured in basal conditions or after AP administration (same experiments as Figs. 1 and 2) in normal (left) and BDL (right) rats. The basal biliary secretion of AP was markedly (P Ͻ .01) higher in BDL rats than in normal rats. When AP was intravenously administered, its biliary concentration and secretion increased more than 6-fold over basal values both in normal and BDL rats. Biliary AP secretion begins to be significantly higher (P Ͻ . without AP both under basal conditions and during stimulation with secretin (Table 1, Fig. 5 ). The activity of the Cl Ϫ /HCO 3 Ϫ exchanger was only inhibited by AP when IBDU were preincubated for 30 minutes and then perfused with the enzyme. Under these experimental conditions, the maximal rate of pH i recovery after Cl Ϫ readmission was lower (P Ͻ .05) in IBDU preincubated and perfused with AP compared with paired controls (Table 1, Fig.  5 ). In these experiments, the secretin stimulation of Cl Ϫ /HCO 3 Ϫ exchanger was abolished by AP. Secretin increased the rate of alkalinization after Cl Ϫ removal as well as the pH i recovery rate after Cl Ϫ readmission in controls but was without effect in IBDU preincubated and perfused with AP (Table 1, Fig. 5 ). The inhibitory effects of AP on Cl Ϫ /HCO 3 Ϫ exchanger activity in IBDU occur also at the lower concentration of 2 U/mL but with a longer time of preincubation (60 minutes). IBDU preincubated for 60 minutes and superfused with 2 U/mL AP showed a rate of pH i recovery after Cl Ϫ readmission significantly (P Ͻ .05) lower than in paired controls (0.124 Ϯ 0.014 [n ϭ 15] vs. 0.186 Ϯ 0.015 [n ϭ 15] pH units/min; P Ͻ .05) and showed no response to secretin. Secretin, in fact, increased the rate of pH i alkalinization after Cl Ϫ removal and the rate of pH i recovery after Cl Ϫ readmission, respectively, by 35 Ϯ 3% and 39 Ϯ 4% in control IBDU (P Ͻ .05; n ϭ 15) but was without effects (Ͻ3% increase; not significant) in IBDU preincubated for 60 minutes and perfused with 2 U/mL AP (n ϭ 15).
Heat-inactivated AP showed (preincubation and perfusion) no significant effect on the basal as well secretin-stimulated Cl Ϫ /HCO 3 Ϫ exchanger activity (Table 1) . Because Cl Ϫ /HCO 3 Ϫ exchanger is apically located and is in contact with biliary AP, we evaluated whether the activity of the anion exchanger could be affected by apical exposure to AP. For this purpose, AP was microinjected into the IBDU luminal space (20 U/mL in saline), and Cl Ϫ /HCO 3 Ϫ exchanger was evaluated in comparison with saline-microinjected paired controls. After AP apical exposure, the Cl Ϫ /HCO 3 Ϫ exchanger basal activity was decreased (P Ͻ .05) during Cl Ϫ readmission, and the secretin stimulatory effect on pH i changes induced by Cl Ϫ removal/readmission was abolished ( Table 2 , Fig. 5 ). Similar findings were obtained after microinjection of the hepatic AP isoform (Sigma, type IX), which decreases that rate of pH i recovery after Cl Ϫ readmission (0.115 Ϯ 0.011 [n ϭ 6] vs. 0.165 Ϯ 0.013 [n ϭ 6; saline-injected controls] pH units/min; P Ͻ .05) and completely abolished the effects of secretin. In fact, when secretin was administered in IBDU previously microinjected with the hepatic AP isoform, the hormone failed to stimulate the maximal rate of pH i increase after Cl Ϫ removal (AP plus secretin ϭ 0.129 Ϯ 0.011 vs. AP alone ϭ 0.121 Ϯ 0.012 pH units/min) as well as the maximal rate of pH i recovery after Cl Ϫ readmission (AP plus secretin ϭ 0.136 Ϯ 0.016 vs. AP alone 0.128 Ϯ 0.016 pH units/min; n ϭ 6). This indicates that, by acting on the cholangiocyte apical surface, AP decreases Cl Ϫ /HCO 3 Ϫ basal activity and blocks the secretin stimulatory effect. Heat-inactivated AP (intestinal isoform) microinjected into the IBDU luminal space showed no effect on basal and secretin-stimulated Cl Ϫ /HCO 3 Ϫ ( Table  2) .
Basal (25 Ϯ 3.8 fmol/100,000 cells) and secretin-induced (54 Ϯ 6.1 fmol/100,000 cells) cAMP levels in cholangiocytes isolated from BDL rats (n ϭ 5) were unaffected by preincubation (45 minutes) with 20 U/mL AP (basal: 22 Ϯ 4.1, n ϭ 5; secretin: 58 Ϯ 7.2 fmol/100,000 cells; n ϭ 5), thus excluding interference with the secretin signal transduction. The effect of levamisole on the Cl Ϫ /HCO 3 Ϫ exchanger activity was evaluated in IBDU preincubated for 45 minutes and superfused with 1 mmol/L levamisole (dissolved in the incubation medium or perfusion solution). The maximal rate of pH i increase after Cl Ϫ removal as well as the maximal rate of pH i recovery after Cl Ϫ readmission was significantly higher in IBDU preincubated with levamisole than in paired controls (Table 3 ). This experiment indicated that in IBDU, the inhibition of endogenous AP activity by levamisole induces activation of the exchanger. In contrast, levamisole failed to influence the Cl Ϫ /HCO 3 Ϫ activity of IRHC. In fact, IRHC preincubated for 45 minutes and superfused with 1 mmol/L Ϫ exchanger activity was evaluated by measuring the maximal rate of alkalinization after Cl Ϫ removal (equimolar substitution with gluconate) and the maximal rate of pH i recovery after Cl Ϫ readmission. Upper left tracing: secretin increases the maximal rate of alkalinization after Cl Ϫ removal and of pH i recovery after Cl Ϫ readmission in comparison with the first control maneuver. Middle left tracing: AP perfusion did not change the maximal rate of alkalinization after Cl Ϫ removal and of pH i recovery after Cl Ϫ readmission (middle tracing vs. upper tracing). In the presence of AP, secretin increases the maximal rate of alkalinization after Cl Ϫ removal and of pH i recovery after Cl Ϫ readmission in the same fashion as in the absence of AP (middle tracing vs. upper tracing). Lower left tracing: preincubation (30 minutes) and perfusion with AP decreases the maximal rate of pH i recovery after Cl Ϫ readmission in comparison with control IBDU incubated with saline (lower tracing vs. upper tracing). The secretin stimulatory effect is lost (second maneuver vs. first maneuver lower tracing). Tracings are representative of data shown in Table 1 . Right tracings: Microinjection of AP (lower) decreases the maximal rate of pH i recovery after Cl Ϫ readmission (first maneuver) in comparison with saline microinjected controls (first maneuver upper tracing). The secretin stimulatory effect is lost (second maneuver vs. first maneuver lower tracing). Tracings are representative of data shown in Table 2. levamisole, showed a maximal rate of pH i increase after Cl Ϫ removal as well as the maximal rate of pH i recovery after Cl Ϫ readmission, which were similar with respect to paired controls (Table 3) . Figure 7 shows the uptake and intracellular transport of AP, which was histochemically evaluated in IBDU incubated at different time intervals with AP. Control IBDU showed a weak positivity for AP activity localized only along the apical membrane. After 10 minutes of incubation, AP activity was mainly localized in the basolateral region of the cytoplasm (85.5 Ϯ 3.1% of total cell staining, Fig. 7A ), whereas only 14.5 Ϯ 1.4% of total cell AP was in the apical region of the cytoplasm (P Ͻ .01 vs. basolateral, Fig. 7A ). After 30-minute incubation, AP staining involves both the basolateral and apical regions of the cytoplasm ( Fig. 7B ; basolateral: 52.2 Ϯ 2.9% vs. apical: 47.8 Ϯ 1.8%; P Ͻ .01 vs. 10-minute values).
Uptake and Intracellular Distribution of AP in IBDU and IRHC.
To evaluate for apical uptake of AP in the biliary epithelium, a retrograde perfusion of the enzyme was performed from the common bile duct of isolated portal tissue (i.e., the biliary tree) completed devoid of hepatocytes. After the retrograde perfusion of AP, a strong AP activity (histochemistry) was observed in the whole cytoplasm of cholangiocytes lining intrahepatic bile ducts with a 30-to 100-m diameter (Fig. 8) . The intensity of the staining detected in the cytoplasm of 30 bile ducts injected with AP, was 3.5 Ϯ 0.5 times the values determined in 30 control ducts perfused without AP (P Ͻ .01). This is suggestive for an apical uptake of AP by cholangiocytes (Fig. 8) .
The uptake and intracellular distribution of AP was also evaluated in IRHC incubated with medium containing or not 20 U/mL AP for 30 minutes. Control IRHC showed a slight AP activity in the canalicular membrane or no staining at all (Fig.  7C) . Incubation with AP did not significantly increase the staining either in the basolateral pole or cytoplasm of IRHC with respect to controls (Fig. 7D) . A low increase of AP activity was only observed along the canalicular membrane of IRHC after 30 minutes of incubation with the enzyme (Fig.  7D) , as observed in 80% of treated IRHC.
Molecular Expression of AP mRNA in Pure Cholangiocytes From
Normal and BDL Rats. A 346-bp message was detected in total liver RNA but not in yeast transfer RNA by RT-PCR (positive and negative controls respectively; Fig. 9 ). The expression of AP mRNA was low in normal cholangiocytes but markedly increased in cholangiocytes from BDL rats (Fig. 9) . GAPDH mRNA (the housekeeping gene) was similar in cholangiocytes from normal or BDL rats. The PCR product was 100% homologous to the published sequence 21, 22 for hepatic rat AP mRNA.
Effect of Chronic Administration of AP on Liver Morphology and
Bile Secretion. Morphologic examination of liver sections taken from rats treated for 2 weeks with AP (Figs. 10B and C and 11B) did not show evidence of tissue damage, but several canalicular spaces appeared enlarged (Fig. 10C) . In APtreated rats several canaliculi in the portal area showed a strong ␥-GT staining (Fig. 10B and C) , whereas a few were positive in saline-treated controls (Fig. 10A) . Bile ducts appear also ␥-GT positive in AP-treated as well as in salinetreated controls (Fig. 10A, B, and C) .
AP activity on saline-treated control livers was localized in cholangiocytes as well as along the bile canaliculi in the periportal region (Fig. 11A, histochemistry) . AP chronic treatment (Fig. 11B) increased the AP activity in both cholangiocytes and hepatocytes, which appeared strongly stained in the whole lobule. This was similar to that observed in 1-week BDL rats (Fig. 11C) , where AP was also uniformly distributed in all lobular zones without the preferential periportal distribution of AP seen in the normal rat liver (Fig. 11A) . Moreover, the AP staining often appears with a "punctate" pattern in the normal liver (Fig. 11A) , whereas in AP-treated (Fig. 11B) and BDL ( 
DISCUSSION
AP is a nonspecific protein phosphatase localized in the apical pole of both hepatocytes and cholangiocytes in direct contact with transporters that play a major role in the process of bile formation. [1] [2] [3] [4] [5] [12] [13] [14] [15] The AP serum levels are of major clinical relevance being their increase a marker of cholestasis. This increase is caused by retrograde reflux of biliary AP, enhanced hepatic synthesis and enzyme release into the serum, and induction of the intestinal AP isoform. [12] [13] [14] [15] Despite the clinical and pathologic significance, the functions of AP and the role in the progression of cholestatic diseases are virtually unknown.
We investigated the involvement of AP in the regulation of the secretory functions of the intrahepatic biliary epithelium. The BDL rat was used as a classic experimental model to investigate the physiology of the biliary epithelium being characterized by a marked proliferation of bile ducts and ductules, which allow amplification of the properties of these structures. 1 In addition, IBDU were used as simple experimental models of ductal bile formation. 18 The intestinal isoform of AP was used for the following reasons: (1) the excessive cost of hepatic isoform makes perfusion studies in -FIG. 8 . Micrograph of an isolated bile duct after AP retrograde injection. AP (intestinal isoform; 20 U/mL dissolved in KRH) was infused through a nonrecirculating system at a flow rate of 0.1 mL/min for 30 minutes, from the common bile duct of isolated portal tissue completed devoid of hepatocytes. A strong AP activity (histochemistry) was observed in the whole cytoplasm of cholangiocytes (arrows). The intensity of the staining detected in the cytoplasm of 30 bile ducts injected with AP was 3.5 Ϯ 0.5 times the values determined in 30 control ducts perfused without AP. Nuclei were counterstained with methyl green (original magnification ϫ150). accessible, (2) inhibitory effects against CFTR have been demonstrated for intestinal AP, 6, 7 and (3) in postcanalicular cholestasis the enhanced AP serum levels comprise both the intestinal and hepatic isoforms. 11, 14 However, microinjection studies were also performed with AP hepatic isoforms showing similar inhibitory effects against basal and, mainly, secretin-stimulated Cl Ϫ /HCO 3 Ϫ exchanger activity. Acute Administration of AP Inhibits Ductal Bile Secretion. We showed that acute AP intravenous administration has no effect in normal rats but induces a significant inhibition of bile flow and bicarbonate secretion in BDL rats in which the mass of intrahepatic biliary epithelium and its contribution to generation of bile flow is markedly increased. 1, 2, 16 This indicates that the target of the AP inhibitory effect is the biliary epithelium. This conclusion was further supported by the abolishment of the choleretic effect of secretin, a hormone that acts on receptors localized exclusively on cholangiocytes. 1-3 AP failed to influence the choleretic effect of TCA and glucagon, the latter acting through a stimulation of Cl Ϫ /HCO 3 Ϫ exchanger in hepatocytes. 24 Altogether these findings indicate that AP specifically affects the secretory processes of the intrahepatic biliary epithelium rather than those of hepatocytes. This conclusion was directly confirmed by the inhibitory effect of AP on fluid secretion in IBDU. In this experimental model, basal and secretin-stimulated bicarbonate-rich ductal secretions are mainly driven by the apically located Cl Ϫ / HCO 3 Ϫ exchanger and CFTR. 5, 18 We showed that when AP, but not heat-inactivated AP, is directly applied in contact with the cholangiocyte apical pole (intraluminal microinjection), the basal activity of the Cl Ϫ /HCO 3 Ϫ exchanger was immediately inhibited, and mainly the stimulatory effect of secretin was abolished. Because secretin acts by activating CFTR, as a prerequisite for anion exchanger stimulation, 3, 5, 18 our findings suggest that AP blocks CFTR activation by secretin. These findings were reproduced when IBDU were preincubated (Ͼ30 minutes) with AP (basolateral exposure). Because a transcytosis of AP occurs in cholangiocytes (see above), this indicates that the accumulation of AP in the cholangiocyte apical pole is crucial for the inhibitory effect on Cl Ϫ /HCO 3 Ϫ and CFTR. We have also excluded that AP may affect the secretin intracellular signal transduction pathway because basal and secretin-induced cAMP levels were unaffected by 20 U/mL AP in isolated cholangiocytes. A toxic, nonspecific effect of the AP used could be excluded because viability, pH i , and basal and secretin-stimulated cAMP levels in isolated cholangiocyte were all unaffected by AP. Furthermore, our experiments were also controlled (protein controls) by using heat-inactivated AP, which showed no measurable effect on (1) bile flow and biliary bicarbonate excretion in BDL rats, (2) fluid secretion in perfused IBDU, and (3) basal and secretinstimulated Cl Ϫ /HCO 3 Ϫ exchanger after intraluminal microinjection in IBDU. This allows us to conclude that our findings represent a nonspecific effect of protein load to the secretory apparatus.
The exact mechanism of action of AP was not shown in the present study. Previous studies in other cells expressing or transfected with CFTR, including pancreatic duct cell lines, 7 Chinese hamster ovary, and human airway epithelial cells, 6 have shown that when CFTR is activated by a PKA catalytic subunit, exogenous AP dephosphorylates and inactivates CFTR. Furthermore, in unstimulated cells or membranes, inhibitors of AP, including sodium fluoride, levamisole, and bromotetramisole, may activate CFTR. 6, 7 These studies, however, have been performed in inside/out membrane patches with application of AP or its inhibitors from the cytoplasmic side where the CFTR regulatory domain is located. 9, 28 Because AP is an ectoenzyme anchored on the cell surface by glycosylated phosphatidylinositol, 29, 30 a regulatory effect on CFTR is questionable. However, the existence of cytoplasmically oriented AP cannot be completely excluded, 7, 29, 31 thus leading to the hypothesis 7 that membrane-associated AP is functionally and physically linked with CFTR protein and participates in maintaining CFTR in the quiescent inactive state and in its functional regulation. 7 This could specifically occur during increased synthesis (cholestasis) or overload of exogenous AP FIG. 9 . RT-PCR analysis in Poly(A ϩ ) mRNA obtained from pure cholangiocytes isolated from normal and BDL rats. The message for AP was very slight in normal cholangiocytes but was markedly expressed in cholangiocytes from BDL rats. GAPDH mRNA (the housekeeping gene) was similarly expressed in cholangiocytes from both normal and BDL rats. Poly(A ϩ ) mRNA from rat total liver and yeast transfer RNA were used as the positive and negative controls.
such as in our experimental conditions in which cholangiocytes appear fully enriched of AP. Our findings that levamisole enhances biliary bicarbonate excretion in BDL rats and activates the Cl Ϫ /HCO 3 Ϫ exchanger in IBDU further support this hypothesis. Levamisole is an AP inhibitor with an effect 10-fold higher against the hepatic than intestinal isoform, 32 and thus, the stimulatory effect on bile flow and bicarbonate excretion indicate that endogenous AP, whose synthesis is increased in BDL rats, [12] [13] [14] [15] is of relevance in the down-regulation of secretory processes of biliary epithelium. Furthermore, we showed that levamisole activates the Cl Ϫ /HCO 3 Ϫ exchanger in IBDU, an effect reproducing that previously described for okadaic acid, 5 a specific inhibitor of the protein phosphatase 1 and 2A. The lack of effects of levamisole on the activity of Cl Ϫ /HCO 3 Ϫ exchanger in isolated hepatocytes, which do not express CFTR, 5 suggests that (1) biliary epithelium rather than hepatocytes is responsible for the increased biliary bicarbonate excretion induced in vivo, in BDL rats, by levamisole; and (2) the inhibition of endogenous AP activity by levamisole activates the Cl Ϫ /HCO 3 Ϫ exchanger only in cells expressing CFTR. This further supports our hypothesis that AP participates together with other protein phosphatases in the reversible phosphorylation of CFTR in cholangiocytes and that this regulation is a major determinant of the state of CFTR activation.
An alternative explanation of our findings is that AP acts as ATPase. AP could hydrolyze the ATP bound to the CFTR nucleotide binding domains, which is crucial for CFTR activation. 9, 28 Furthermore, ATP may regulate cholangiocyte secretory processes acting as autocrine/paracrine signals that modulate Cl Ϫ conductance via activation of apical purinergic receptors 10 ; the release of ATP into the ductal lumen and its degradation being important determinants of purinergic receptor activation. 10 Thus, AP could influence cholangiocyte secretory processes by regulating either ATP release through cholangiocyte apical membrane or the hydrolysis of intraluminally released ATP.
The Intrahepatic Biliary Epithelium Plays a Major Role in the Uptake and Biliary Secretion of AP and Displays Enhanced Gene
Expression of AP During Bile Duct Ligation. We then investigated the biliary secretion of exogenous-administered AP and we showed that the intrahepatic biliary epithelium also plays a role in the uptake and biliary secretion of this enzyme. The amount of AP secreted in bile after AP intravenous administration was 10-fold higher in BDL rats compared with normal rats, indicating that when bile duct mass is increased (BDL), the hepatic clearance of the enzyme is markedly enhanced. Basal biliary AP secretion was also higher in BDL rats than in normal rats, and this finding, previously shown by others, 11 also indicates that the secretion of endogenous AP is enhanced in BDL rats. Exogenous-administered AP appeared in bile only 20 to 30 minutes after administration (Fig. 3) , and this should exclude a paracellular transport of AP via tight junctions. Indeed, transcellular transport of exogenous AP in the intrahepatic biliary epithelium was directly shown by the histochemical study in IRHC and IBDU incubated with AP. During 20-minute incubation with AP, IRHC only showed a slight increase of AP in the canalicular membrane. On the FIG. 10 . ␥-GT histochemistry in liver sections from a rat treated in vivo with alkaline phosphatase for 14 days (B and C) and from a saline-treated control (A). Bile ducts (arrows) show specific ␥-GT staining in AP-treated (B and C) as well as in control rats (A). Several canaliculi in the portal area appear strongly stained in AP-treated rats (B and C), whereas only a few were observed in control sections (A). In AP-treated rats (B) the liver parenchyma does not show morphologic evidence of necrosis but the lumen of several ␥-GT-positive canaliculi appears enlarged as shown (B; arrowhead; original magnification ϫ50) and at higher magnification (C; original magnification ϫ100).
contrary, IBDU showed a marked increase of AP staining, which sequentially (over time) involves first the basolateral region of the cytoplasm and thereafter both the basolateral and apical regions. This highlights a new function of the biliary epithelium, which is biliary secretion of serum AP. Transcytosis of AP in cholangiocytes is only significant after 10 minutes, which is more consistent with receptor-mediated rather than fluid-phase endocytosis. The uptake of AP in the liver is mediated by the asialoglycoprotein receptor, 33 the expression of which in cholangiocytes has not been investigated. In the rat, exogenous infused rat intestinal AP is cleared in the liver by mannose/N-acetylglucosamine-specific receptors, 33, 34 and a large difference has been shown between different AP isoforms (liver, bone, and placental) in relation with their carbohydrate structure and with the amount of sialic acid. 34 In the serum, low levels of a high molecular mass AP are present, and they increased during cholestasis or hepatic malignancy. 35 Whether this type of AP may be cleared by the biliary epithelium is unknown; however, it may by hydrolyzed by plasma phospholipases with delivery of low molecular mass AP. 36 We have then shown that the expression of AP mRNA was very low in normal cholangiocytes but markedly increased in cholangiocytes from BDL rats. This is strongly suggestive for a role of the intrahepatic biliary epithelium in the enhanced hepatic synthesis of AP occurring during bile duct ligation and further supports the role of AP in the counteregulation of cholangiocyte secretory processes. In cholangiocytes isolated from BDL rats, in fact, the basal and secretin-induced ductal secretion is markedly enhanced because of the overexpression of secretin receptor and increased secretin-induced cAMP levels. 16 The enhanced AP in cholangiocytes could prevent pressure-related damage of the biliary tree by turning off ductal secretion.
Chronic Treatment With AP Promotes Enlargement of Canalicular
Spaces, Induces ␥-GT in the Liver, and Inhibits Bile Secretion. Having shown that AP inhibits the secretory processes in the biliary epithelium, we then investigated the effect of a prolonged administration of AP on liver morphology and bile secretion. The dose of AP chosen was the one that was able to significantly increase serum levels and hepatic concentration (histochemistry) of the enzyme, thus simulating cholestasis. In the liver of AP-treated rats, AP staining was markedly more intense and diffuse than in saline-administered controls and displayed features similar to the BDL rat liver. In the hepatocytes, AP still persisted only in the canalicular membrane. However, within the lobule, the enzyme was uniformly distributed and the lobular gradient (higher AP in periportal areas) seen under normal conditions was completely lost as occurs in chronic cholestasis. 26, 37, 38 In addition, the morphologic study revealed some signs of postcanalicular cholestasis, including dilatation of canalicular spaces and induction of ␥-GT, which appear intensely expressed in periportal hepatocytes. 26, 37, 38 The functional study showed a decreased bile flow and bicarbonate secretion (no effect with heat-inactivated AP), and this, in accordance with the morphologic study and the enhanced BS serum levels, should indicate a cholestatic effect of AP (ductular cholestasis). In this scenario, the FIG. 11 . AP histochemistry in liver sections taken from rats chronically treated with AP (B) or with saline (A); for comparison AP histochemistry in a 1-week BDL rat (C; no treatment) is shown. In normal rats (A), bile canaliculi react irregularly, mostly in periportal areas, whereas no cytoplasmic staining was evident in hepatocytes. Bile ducts showed positivity for AP staining, and a slight activity was also observed in the endothelium of the arteries. The liver taken from an AP-treated rat (B) showed a stronger AP activity in bile ducts (arrow). The staining was also observed in the canaliculi in the whole lobule (B), with a pattern and a distribution similar to that observed in the liver after 1-week bile duct ligation (C). Both AP-treated liver (B) and BDL liver (C) showed a uniform distribution of AP in the whole lobule without the preferential periportal distribution seen in normal rat liver (A). Nuclei were counterstained with methyl green (original magnification [A and B] ϫ25, [C] ϫ100).
decreased BS biliary secretion together with enlarged bile canaliculi could be the result of a back pressure phenomenon caused by the impaired ductal bile flow or an effect of AP on BS transport. The inhibition of bile secretion was achieved with a markedly lower hepatic enrichment of AP compared with BDL rats (see histochemistry) in which the AP inhibitory effects could be even more important.
In conclusion, we showed that AP plays inhibitory effects on bile secretion by specifically targeting the intrahepatic biliary epithelium and that chronic AP administration reproduces features of intrahepatic cholestasis. These findings lead to the suggestion that AP displays an important role in the counter regulation of secretory stimuli by acting at the level of the biliary epithelium apical pole. This function should play an important protective role for the biliary tree as well as for the whole liver. In cholangiocytes, after secretory stimuli activating CFTR and/or Cl Ϫ /HCO 3 Ϫ exchanger, the intervention of AP may facilitate the cell to return to a quiescent unstimulated state. Because the secretory activity of cholangiocytes is regulated by a balance between kinases and phosphatases, the increased AP during obstructive cholestasis should decrease the intrahepatic biliary epithelium secretory activities, thus avoiding a further increase in bile pressure that could be very dangerous for the entire liver. When obstruction is resolved, the clearance of AP via bile secretion may lead to a normalization of secretory activities.
